Ursodiol is a bile acid indicated for dissolution of gallbladder stones and primary biliary cholangitis. We supply it to US manufacturers of capsules and tablets.
Data from PubChem (CID 31401) and FDA’s substance registry
CAS number
128-13-2
Molecular formula
C24H40O4
Molecular weight
392.6g/mol
FDA UNII
IUPAC name
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
InChIKey
RUDATBOHQWOJDD-UZVSRGJWSA-N
- Appearance
- White, bitter-tasting powder of crystalline particles.
- Solubility
- Practically insoluble in water. Freely soluble in ethanol and glacial acetic acid, slightly soluble in chloroform and sparingly soluble in ether.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Made from bile acids of bovine origin, so the TSE/BSE statement and the origin of the starting material are part of every qualification.
On the US market
- Reference product
- ActigallNDA 019594
- Approved ANDAs
- 16 with a marketed product
- Approved forms and strengths
- Capsule 150 mg, 200 mg, 300 mg, 400 mg
- Tablet 250 mg, 500 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com